Bovine hypothalamus contains a nonpeptidic substance that inhibits purified Na+/K+-transporting ATPase
By regulating the electrolyte balance of cells and organs, the plasma membrane Na+/K+-transporting ATPase [ATP phosphohydrolase (Na+/K+-transporting), EC 3.6.1.37; Na+/K+-ATPase] is responsible for many fundamental cellular and physiologic processes such as cell volume regulation, the setting of membrane potential, regulation of cardiac contractility, and renal Na' reabsorption. The enzyme also serves as the cellular receptor for the digitalis glycosides (1) . Relatively little is known about the endogenous regulation of the enzyme. Catecholamines (2-4), thyroid hormone (5), aldosterone (6) , and vanadium (7) have all been linked to either direct or indirect effects on enzyme activity. However, the fact that the only known specific regulatory ligand, digitalis, is a substance from the plant kingdom has given rise to the notion of the existence of a specific endogenous physiologic regulator of mammalian origin, which might functionally resemble the cardiac glycosides. The concept of an "endogenous digitalis" has been made more provocative by a growing body of experimental evidence for a circulating Na+/K+-ATPase inhibitor that would play a physiologic role in the normal natriuretic response to extracellular fluid volume expansion (8) and a pathogenetic role in a prevalent human disease, hypertension (9) . The postulated action of this substance is the modulation of renal tubular Na' reabsorption and vascular smooth muscle tone by regulating Na+/K+-ATPase activity (10) . Indeed, the exogenous analogue of this putative regulator, digitalis, a potent inhibitor of the Na+/K+-ATPase, has been shown to cause both natriuresis (11) and an increase in vascular resistance (12) , although these are not its major pharmacological effects.
Much effort has been expended in many laboratories to identify and characterize a plasma, urinary, or tissue inhibitor of Na+/K+-ATPase; still a dearth of functional studies exist, and the definitive structure of such an inhibitor is not known (13) . Furthermore, the degree to which various candidate compounds are truly "digitalis-like" in either structure or function remains controversial because even those substances characterized in the greatest biochemical detail (14-16) manifest some differences from the cardiac glycosides.
One cardinal criterion for biological activity functionally analogous to the cardiac glycosides would be the demonstration of positive inotropic effects in cardiac muscle. We have isolated and partially purified from bovine hypothalamus a low-molecular-mass, nonpeptidic substance that satisfies a number of essential criteria for a physiologic regulator of Na' pump activity in vivo (17) . It inhibits the purified Na+/ K+-ATPase reversibly, with high affinity (K, = 1.4 nM) (18); it's effects are specific for the Na+/K+-ATPase in the plasma membrane (14) , and it acts only from the extracellular surface of the cell (14, 17) , consistent with the concept of a circulating inhibitor of the Na+/K+-ATPase. Thus, while certain of the biologic effects of this hypothalamic substance are the same as those of the cardiac glycosides, important differences in its mechanism of inhibition of the Na+/K+-ATPase have been discovered (14, 18) . Its potential role as regulator of renal Na' excretion was strengthened by the demonstration of binding and dissociation reactions in intact renal tubular cells consistent with physiologic regulation in vivo (19) . But physiologic effects in cardiac cells remained unknown, although preliminary experiments documented inhibition of purified cardiac Na+/K+-ATPase (20) . To further explore the possibility that this hypothalamic inhibitory factor (HIF) could have physiologic actions in cardiac tissues, its effects on Na' pump activity, cytosolic free Ca2l ([Ca2+]i) accumulation, and contractility were studied in spontaneously contracting, neonatal rat myocytes in culture.
We report here that HIF is a potent inhibitor of the Na' pump in these cells, with effects on [Ca2+]i changes and contractile response parallel to those of the cardiac glycoside ouabain. Our results also show that at the same [Ca2"] in the myocytes, ouabain is toxic, whereas the endogenous factor is not.
MATERIALS AND METHODS
Preparation of HIF. The Na+/K+-ATPase inhibitor was prepared from bovine hypothalamus as described (14) .
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Briefly, hypothalami collected fresh and frozen immediately on dry ice were thawed, homogenized, and extracted in methanol/water (4:1, vol/vol). Methanol was removed by flash evaporation, and lipids were removed by extraction of the remaining aqueous phase with petroleum ether and chloroform. Initial separation of HIF was done by using lipophilic gel chromatography (14) . Further purification was accomplished by using successive cation-and anion-exchange chromatographies (21) . Purified HIF is free of vanadate (emission spectroscopy), NH4 ion (reductive amination, Sigma kit 170-A), and free fatty acids and lysophospholipids (GC/MS), which have been shown to interfere in pertinent bioassays. One unit of HIF in the myocyte studies is defined as that amount of inhibitor that inhibits ouabain-sensitive K+ transport by 50%, as determined by 86Rb+ uptake into human erythrocytes (14) . One unit of HIF in this assay also inhibits the Na+/K+-ATPase purified from canine renal medulla by 50%, as measured spectrophotometrically in a kinetic coupled-enzyme assay (18 'Rb+ Influx Measurements. Na' pump activity was estimated in the cultured cardiac cells as the difference in 86Rb+ uptake seen with and without 5 mM ouabain, following the method of Panet et al. (23) . Incubations were continued for up to 10 min (period of linear uptake of the isotope) (24) .
, were detected using the fluorescent probe fura-2 (25) . Rectangular glass coverslips with attached myocytes were placed in buffered salt solution (BSS; 140 mM NaCI/5 mM KCI/1 mM CaCl2/1 mM MgCI2/10 mM glucose/i mM Na2HPO4/10 mM Hepes-Tris, pH 7.4) to which was added 5 ,M fura-2/AM and incubated for 1 hr in humidified 5% C02/95% air at 37°C. Additional loading medium was added, and incubation was continued for 15 min to complete the hydrolysis of fura-2/AM. The cells were washed and incubated an additional 30 min in BSS (26) . Coverslips with loaded myocytes were inserted into a thermostated (37°C) cuvette containing 2 ml of BSS and various additions of HIF or ouabain as indicated. Measurements of Myocyte Contractility. Contractility, determined as amplitude of systolic cell motion (ASM) and beating frequency were measured in individual cells by using a phase-contrast microscope video motion-detector system according to the method of Barry et al. (27) . A glass coverslip with attached cultured myocytes was placed in a chamber provided with inlet and exit ports for medium perfusion. The chamber was enclosed in a Lucite box at 370C and placed on the stage of an inverted phase-contrast microscope. The cells were covered with 1 ml of medium containing HIF or ouabain. Motion was monitored by a low-light-level TV camera attached to the microscope and calibrated with 262 raster lines. The motion-detector monitors a selected raster line segment and provides new position data every 16 msec for an image border of a microsphere within the cell layer moving along the raster line. The analog voltage output from the motion detector is filtered at low-band pass filter and calibrated to indicate actual Aum of motion, and the derivative is obtained electronically and recorded as velocity of motion in um/sec. Rate, amplitude, and velocity of contraction remained stable for several hours during control perfusions. The changes in the contractility induced by ouabain or HIF were calculated in comparison with the contractility of the same cells before addition of ouabain or HIF. Position of maximal relaxation and shifts of this baseline (AMR) which indicate toxicity can be reliably measured by the video method used (26, 28) . RESULTS HIF Effects on Myocyte Na+ Pump Activity. Fig. 1 shows the effects of HIF and ouabain on total 'Rb+ uptake into the cultured cardiac cells. In this experiment, to ensure saturation binding, myocytes were preincubated for 20 min with HIF (2 units/ml) or ouabain (5 mM), or both before adding 86Rb+ to run the 10-min flux. Ouabain decreased uptake from control levels of 810 nmol/mg of protein to 210 nmol/mg (74%), whereas HIF at 2 units/ml decreased the uptake from control levels to 377 nmol/mg (54%). The combination of ouabain plus HIF was not additive, indicating that HIF inhibitory effects are specific for K+ transport through the Na+/K+-ATPase. In this experiment, HIF at 2 units/ml thus inhibited ouabain-sensitive K+ transport by 74%. In subsequent experiments, Na' pump activity is defined as the difference in 86Rb+ uptake seen with and without 5 mM ouabain. Fig. 2 shows the effects of increasing doses of HIF on Na+ pump activity in the myocytes. The largest dose of HIF tested (4 units/ml) inhibited ouabain-sensitive K+ uptake by 90%, whereas the ID50 for pump inhibition occurred at an HIF concentration of 0.55 unit/ml. Inhibition of transport by HIF progressed as a function of exposure time of cells to inhibitor ( Fig. 2, Inset) . Neonatal rat myocytes appear to have a relatively high affinity for HIF; the ID50 = 0.55 unit/ml contrasts with an ID50 = 15 units/ml found in activetransport-inhibition studies with porcine renal tubular cells in culture (19) . HIF Effects on Myocyte Contractility. The effects of different doses of HIF on cell contractility, measured as ASM, and beating frequency were measured using the phase-contrast video motion-detection system and compared to the effects of ouabain. Results of a typical experiment are shown in Fig. 4 .
Ouabain (5 x 10-7 M) (Fig. 4B) , a maximally inotropic but nontoxic dose -in these cells (26) , increased ASM by 41% and decreased beating frequency compared to the same cells in the control period (Fig. 4A) . There was no change in the position of maximal relaxation, indicating "therapeutic range" but nontoxic effects with this dose of the cardiac glycoside. Ouabain at 1 AuM (Fig. 4C) showed a decrease in ASM, an elevation in the position of maximal relaxation, and an increase in beating frequency, all indicating "toxic-range" effects of this higher dose on the contracting myocytes. HIF at 1 unit/ml (Fig. 4E) increased ASM 39% compared to control (Fig. 4D) , with a decrease in beating frequency and no change in the position of maximal relaxation. After a 1-min "washout," during which the same cell was perfused with HIF-free buffer, ASM and beating frequency returned to control levels (Fig. 4F) , indicating rapid reversibility of the positive inotropic effects caused by HIF. Table 2 Fig. 4C ), although the cells showed no manifestations of toxicity at this HIF dose (Table 1, Fig. 4E ).
DISCUSSION
The HIF possesses some of the characteristics ascribed to an endogenous "digitalis-like" compound that has been proposed to act as a natriuretic hormone and a pathogenetic factor in human essential hypertension and, perhaps, as an even more general regulator of Na+/K+-ATPase activity in mammalian cells ( 10-7 M increased ASM by 40% (B) compared to control (A). Ouabain at 1 x 10-6 M produced toxicity, indicated by decrease in ASM, elevation of position of maximal relaxation (AMR), and increase in beating rate (C). HIF at 1 unit (U)/ml enhanced ASM by 40o (E) compared to its control (D). One-minute perfusion of HIF-free buffer returned ASM and beating frequency to control levels (F).
versibility of effects, and specificity for the Na+/K+-ATPase in the plasma membrane (14, 18) . Studies of the mechanism of inhibition of Na+/K+-ATPase by HIF showed similarities and important differences when compared with the effects of the cardiac glycoside ouabain. Like ouabain, HIF binds to the extracellular domain of the enzyme, stabilizes it in an E2-like conformation as judged by fluorescence labeling, and inhibits p-nitrophenylphosphatase activity, a partial reaction of the Na+/K+-ATPase (14) . Significantly different from ouabain, HIF does not support phosphorylation of the Na+/ K+-ATPase from inorganic phosphate and magnesium (14) and has ligand requirements for optimal activity quite different from those of the cardiac glycosides (18) . Based on the available biochemical data, the hypothesis has been advanced that HIF may inhibit Na+/K+-ATPase by influencing the phosphate-binding site on the enzyme and may alter active Na' transport by preventing the cycling of the enzyme between the E1 and E2 conformations, thus preventing the translocation of Na+ and K+ ions across the cell membrane (30) .
Thus, while differences in mechanism of action exist for HIF and ouabain, ultimate biological effects on cation transport in blood cells and ion-transporting epithelia are shared by the two substances. The extent to which HIF might be truly digitalis-like in its biological effects in vivo remained uncertain because HIF actions in cardiac tissues, the primary target for digitalis glycosides, were unknown. The present work addresses this question by studying the effects of HIF on Na+ pump activity, [Ca2+]i accumulation, and contractile Ouabain (0.5 ,uM)
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responses in spontaneously beating neonatal rat myocytes in culture.
Na' pump activity was measured in the myocytes using 86Rb+ as a tracer for active K+ transport into the cells. HIF significantly decreased ouabain-inhibitable K+ transport into the cells, and the combination of HIF and ouabain produced no additive inhibition of K+ transport, indicating HIF inhibitory effects to be specific for K+ transport through the Na+/K+-ATPase (Fig. 1) . The specificity of HIF acting only via pump-mediated cation transport in the myocytes parallels previous findings in human erythrocytes (14) -and cultured renal tubular cells (19) .
HIF-mediated Na+ pump inhibition was dose-dependent and related to exposure time of myocytes to inhibitor (Fig. 2) . Ninety percent of Na+ pump activity in the myocytes was inhibited by the maximal dose of HIF used in these studies. The neonatal rat myocytes appear to have a relatively high affinity for HIF. Thus, the ID50 for these cells was =30-fold less than that for cultured porcine renal tubular cells ( Fig. 2 (Table 1) and was clearly toxic (Fig. 4C) , confirming toxic effects at these levels of [Ca2+], caused by 1 ,M ouabain found in previous studies (26) . HIF at 1 unit/ml raised [Ca2+] , in the same cells to 432 + 18 nM but was accompanied by a stable maximal inotropic effect with no sign of toxicity (Fig. 4E) . These findings suggest that the toxicity caused by ouabain in the myocytes must involve drug interactions with the cell that are more complex than simply inhibition of the Na' pump or that abnormalities in Ca2" metabolism within the cell are occurring in compartments not selectively discernible by the fura-2 method. In any case, HIF, at a dose producing similar pump inhibition [1 ,uM ouabain inhibits the Na' pump by 30% during a 20-min incubation in these cells (24) ] and greater elevations in [Ca2+] , than the toxic dose of 1 AM ouabain, did not produce this toxicity.
The positive inotropic effect induced by HIF was readily reversible. A 1-min perfusion with HIF-free buffer sufficed to completely reverse HIF-induced steady-state augmentation of contractility, returning the cell to baseline ASM and beating frequency (Fig. 4E) . HIF effects appear to be more readily reversible than those of ouabain because a 5-min washout period in ouabain-treated neonatal rat myocytes is required to return enhanced contractility to control levels (34) . The ready reversibility of HIF effects on the contractile response in the cardiac myocytes recalls the rapid reversibility in HIF-induced Na+/K+-ATPase inhibition that occurs in sided (intact cell) preparations (19) but not isolated enzyme (18) , and argues for the possibility that, in contrast to the cardiac glycosides, HIF could be a physiologic regulator of Na+/K+-ATPase activity in vivo.
In summary, HIF potently inhibits the Na+ pump in cultured neonatal rat myocytes. The Na+ pump inhibition induced by HIF in these cells is dose-dependent and associated with augmentation of [Ca2+], content and an increase in contractile force equivalent to that caused by maximal nontoxic doses of the cardiac glycoside ouabain. Comparative studies with HIF and ouabain of pump inhibition and calcium content parameters in treated myocytes suggest that glycoside-mediated cardiac toxicity is more complex than simple elevation of fura-2-measurable increases in [Ca2+] ,.
Further studies of the mechanism by which HIF increases myocyte contractility should provide new insight into the biochemical events associated with positive inotropy and the role of specific endogenous Na+/K+-ATPase inhibition in the physiologic regulation of cardiac function.
